Decision in 3 working days after foreign Covid-19 vaccine firms apply

Sources, however, indicated that price negotiations are likely to happen with the health ministry before a vaccine is allowed entry into the Indian market
The Indian health regulator will take a decision within three working days of a foreign vaccine maker seeking emergency use approval, the Centre said on Thursday in a definite move to accelerate the inoculation process.

Also, the Central Drugs Standard Control Organisation (CDSCO) will work in a time-bound manner for every step connected to vaccine approval. For instance, import licence and registration certificates will be processed within three working days of the approval. In addition, bridging clinical trial protocols must be cleared within seven working days for vaccines approved by international regulators.  

Sources, however, indicated that price negotiations are likely to happen with the health ministry before a vaccine is allowed entry into the Indian market. “The government is looking for multiple Covid-19 vaccines here.  It wants a portfolio of vaccines to improve supplies. However, pricing is an important factor and the Centre would negotiate that with the firms,” said a source in the know. Even after vaccines are granted commercial approval to sell in the private market in future, the pricing regulator is likely to keep a close watch.


Another source claimed that both Pfizer and Johnson & Johnson have initiated talks with the government. The firms did not respond to queries. It is learnt that US major Moderna is in talks with the salt-to-software conglomerate Tata Group to bring its vaccine here.

J&J’s single shot vaccine, however, has received a setback in the US as the USFDA has paused further usage pending investigation of the blood clotting incidents reported in individuals immediately after vaccination. So, technically, the vaccine does not meet the Indian criteria for approval at the moment.

According to the roadmap issued on Thursday,  a foreign vaccine maker can submit an application  to CDSCO seeking approval for ‘restricted use in emergency situation’ either through its Indian subsidiaries or authorized agents. The Drugs Controller general of India (DCGI) will consider such applications and take a decision within three working days.

In keeping with the guidelines outlined in the National Covid-19 Vaccination Programme, the first 100 beneficiaries will be assessed for seven days before a vaccine is rolled out for others. The applicant can initiate bridging clinical studies on Indian volunteers within 30-days of approval. The CDSCO needs to approve such applications for clinical trials within seven days.


The drug regulator, however, has added some caveats.

For example, the Central Drugs Laboratory (CDL) at Kasauli will approve each batch of the vaccine that is to be released for use in the national Covid-19 vaccination programme. The applicant will need to submit safety data on 100 beneficiaries of the vaccine to the CDSCO after it gets the CDL approval.

The DCGI will review the permission granted for restricted use in emergency situations after it receives the results of the bridging study.



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel